We develop generics with proven

therapeutic efficacy and safety of administration

Analyzing and strategically adapting the portfolio according to medical trends is a priority.

Medicines that are predominantly developed through their own research programs complement the company’s traditional portfolio.

They are intended for the treatment of generic infections of the following classes:

All medicines can be given by self-medication.

Antibiotice has the necessary know-how to collaborate with partners from all over the world.

integrated projects
research and realization of registration dossiers
conducting bioequivalence studies
registration of projects with the competent external authorities for marketing purposes